P/B
0,5
Virax Biolabs
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
$3.5M
Market Cap • 9/14/2026
2021
(5 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United Kingdom
Country
Valuation
P/S
282,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
19,1
EPS
—
Market Cap
Market Cap
3,5M
EV
-2,8M
EV/Revenue
-221,9
EV/EBITDA
0,5
EV/EBIT
0,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-205%
Total Yield
-205%
Payout
0%
Retained Earnings
-29,6M
Profitability
Gross Margin
61,9%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
30092,2%
Capex/Revenue
2059,3%
Capex/D&A
70,8%
Capex/OCF
-5,5%
SBC/OCF
—
% PPE
18%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-36,9%
CAGR Op. Income 5Y
58,3%
CAGR Net Income 5Y
49,5%
CAGR OCF 5Y
50,9%
Leverage
N.D./EBITDA
1
Debt/Equity
0%
Current Ratio
10
Quick Ratio
9,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!